PA
FHTX icon

Perceptive Advisors’s Foghorn Therapeutics FHTX Stock Holding History

Perceptive Advisors’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-544,000
Closed -$3.13M – 114
2024
Q2 		$3.13M Buy
+544,000
New +$3.24M 0.08% 89

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors's FHTX Position: Q3 2024 in Review

Perceptive Advisors sold out of Foghorn Therapeutics (FHTX) in Q3 2024, closing a stake of 544,000 shares — an estimated $3.13M sold.

Perceptive Advisors first reported a position in FHTX in Q2 2024 and held it in 1 quarter. The position peaked at $3.13M in Q2 2024. 79 funds tracked by Wall St. Rank hold FHTX as of Q3 2024.

  • Perceptive Advisors reported no remaining Foghorn Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Perceptive Advisors sold 544,000 Foghorn Therapeutics shares in Q3 2024, an estimated $3.13M.
  • Perceptive Advisors first reported a position in Foghorn Therapeutics in Q2 2024 and held it in 1 quarter.
  • Perceptive Advisors's Foghorn Therapeutics position peaked at $3.13M in Q2 2024.
  • 79 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2024.

Based on Perceptive Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.